Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13149938 | 1.00 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| SCHEMBL3099567 | 1.00 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| Hydrochloric Acid SCHEMBL3090994 | 0.98 | MEN1 (0.44) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| Hydrochloric Acid SCHEMBL1989031 | 0.98 | MEN1 (0.44) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| Hydrochloric Acid SCHEMBL16763418 | 0.98 | MEN1 (0.44) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| SCHEMBL24593361 | 0.98 | MEN1 (0.44) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| SCHEMBL9470148 | 0.91 | MEN1 (0.40) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| Hydrochloric Acid SCHEMBL9470146 | 0.89 | MEN1 (0.39) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| SCHEMBL30278792 | 0.87 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL1298246 | 0.86 | MAPT (0.50) | MEN1KMT2AMAPTALDH1A1PPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230295202-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230295202-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230148603-A1 | DIOXAZOLINES AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20230150989-A1 | HERBICIDAL MALONAMIDES | BASF SE (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20220242886-A1 | CHEMICAL COMPOUNDS | CANAAN XII L.P. | 2022-08-04 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20210188879-A1 | CHEMICAL COMPOUNDS | CANAAN XII L.P. | 2021-06-24 | — | — | US | disclosed |
| US-20090227641-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090227641-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090227641-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER, INC. | 2009-09-10 | — | — | US | disclosed |
| WO-2009060278-A1 | CYCLOBUTYL CARBOXYLIC ACID DERIVATIVES | PFIZER INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| EP-2021338-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Pfizer Products Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007132307-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132307-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148603-A1 | DIOXAZOLINES AND THEIR USE AS HERBICIDES | HAX1, HDHD5, CBR3 | MEN1 4510/4885KMT2A 2459/4885MAPT 3857/4885 |
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | MEN1 1450/4885KMT2A 924/4885MAPT 1028/4885 |
| US-20230295202-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | SLC28A1, SLC20A1, SLC29A1 | MEN1 2712/4885KMT2A 4442/4885MAPT 4397/4885 |
| US-20230150989-A1 | HERBICIDAL MALONAMIDES | DDT, DHRS9, CA9 | MEN1 2853/4885KMT2A 1533/4885MAPT 3827/4885 |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | MEN1 1450/4885KMT2A 924/4885MAPT 1028/4885 |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | MEN1 1450/4885KMT2A 924/4885MAPT 1028/4885 |
| US-20210188879-A1 | CHEMICAL COMPOUNDS | JAK2, JAK1, JAK3 | MEN1 1421/4885KMT2A 616/4885MAPT 2460/4885 |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCND1, CCND2, CCND3 | MEN1 871/4885KMT2A 1433/4885MAPT 3368/4885 |
| US-20220242886-A1 | CHEMICAL COMPOUNDS | JAK2, JAK1, JAK3 | MEN1 1421/4885KMT2A 616/4885MAPT 2460/4885 |
| US-20090227641-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCNI, CCNA1, PCNA | MEN1 1531/4885KMT2A 1501/4885MAPT 3088/4885 |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINE1, SERPINA3 | MEN1 2354/4885KMT2A 3594/4885MAPT 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.